The joint venture between IBA and Framatome will leverage Telix’s capabilities to accelerate the production and availability of Astatine-211 in the US market. Louvain-la-Neuve, Belgium, Paris, France, Indianapolis, United States, and Melbourne, Australia, October 19th, 2026, 7 a.m. – Ekalia (company in formation), the joint venture combining IBA’s technological expertise (Ion Beam Applications, EURONEXT) with Framatome’s industrial know-how, has entered into a collaboration agreement with Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, “Telix”), a global leader in radiopharmaceuticals, aimed at accelerating the production of Astatine-211 (At-211) in the United States. Following Ekalia’s planned first site in France, this collaboration marks an important step in the development of a robust, reliable and international infrastructure to support...

Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid OSE Immunotherapeutics to host a KOL webcast on November 4, 2026Nantes, France, October 19, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced the release of the abstract selected for an oral presentation at the upcoming ESMO 2026 Annual Meeting, unveiling topline results from the Combi-TED academic Phase 2 international clinical trial of Tedopi® sponsored by FoRT and evaluating Tedopi® (OSE2101), in combination with either chemotherapy or anti-PD1, as a 2nd line treatment in patients with metastatic...

A major milestone in Cabka’s decarbonization journey Amsterdam, Netherlands – 19 October 2026 – Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext Amsterdam, today announces that its near-term science-based emissions reduction targets have been validated by SBTi Services, the validation body of the Science Based Targets initiative (SBTi). This important milestone provides a clear and measurable pathway for reducing emissions across our operations and value chain. The validation builds on Cabka’s existing progress in reducing the carbon footprint of our operations and products, while continuing to expand the circular economy. Cabka committed to the set near-term science-based...

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). Secures long-term, priority isotope access for Telix’s alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs. First IBA alpha-beam cyclotron to be installed and operated at Telix’s RLS Radiopharmacies site near Philadelphia, PA. Leverages Telix’s vertically integrated U.S. manufacturing and distribution platform, with a framework providing for the parties to evaluate additional installations at RLS sites as demand for 211At develops.MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS,...

Proposed transaction represents a strategic investment in Austria and would support Steyr Motors’ long-term growth and Red Cat’s Blue Ops uncrewed surface vessel strategy SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, today announced a proposed voluntary public purchase offer by Red Cat to acquire all outstanding shares of Steyr Motors AG (“Steyr Motors”), one of the world’s leading companies in the field of customized engines for mission-critical defense and civil applications, for EUR 39.00 per share in cash. The proposed transaction is supported by the Steyr Motors’ anchor shareholder B&C Group and represents a strategic investment in Steyr Motors...

Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer Patient-reported outcomes from phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumoursBasel, 19 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and...

Harvest volumes Q3 2026 (1)Farming Norway 134.0 thousand tonnes  Farming Scotland 11.5 thousand tonnes  Farming Chile 23.5 thousand tonnes  Farming Canada West 7.5 thousand tonnes  Farming Ireland 2.5 thousand tonnes  Farming Faroes 3.0 thousand tonnes  Farming Iceland (Arctic Fish) 4.0 thousand tonnes  Total 186.0 thousand tonnes  Harvest volumes of 186 thousand tonnes were all-time high for a quarter (166 thousand tonnes in Q3 2025). Note:(1) The harvest volumes are provided in gutted weight equivalents (GWT). Additional information Operational EBIT for the Group was seasonally record-high of EUR 275 million (NOK 3 017 million, EURNOK 10.97) in Q3 2026 compared with EUR 112 million in Q3 2025. Blended farming cost was EUR/kg 5.11 in the quarter, down from EUR/kg 5.42 in Q3 2025 equivalent to a cost reduction...

Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC) Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase...